drugset / Trial / NCT06248112

Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets

NCT06248112

Phase 1 Unknown 40 enrolled Bio-innova Co., Ltd
Non-randomizedCrossoverOpen-labelBasic science

Summary

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be a randomized, open-label, single oral dose, full replicated crossover design with four-period, two-treatment, and two-sequence under fasting condition and at least 14 days washout period between the doses.

Timeline

Start
2024-05-06
Primary completion
2024-06-22
Completion
2024-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril Small molecule 97 mg Oral
Subject Valsartan Small molecule 103 mg Oral

Indications

No indication recorded.